RecruitingNot ApplicableNCT06053671

Mos-FED (Mosaicism in Focal Epilepsy Cortical Dysplasia Tissue)

Dissecting mTOR Pathway Mosaicism in FCDII-Harbouring Epileptic Brain and Peripheral Tissue.


Sponsor

King's College Hospital NHS Trust

Enrollment

60 participants

Start Date

Apr 9, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

Focal cortical dysplasia (FCD) is a malformation of brain development, the most common cause of drug-resistant epilepsy and often caused by mutations in mammalian target of rapamycin (mTOR) pathway genes. Patients with FCD develop drug-resistant seizures. This study will look at FCD tissue removed during epilepsy surgery and aims to detect mutations in mTOR pathway genes in brain cells. Secondly, the investigators will establish if evidence of mutations found in brain cells can also be detected as circulating free DNA (cfDNA) in blood. By looking at which genes are made into proteins in individual cells found in epilepsy surgical tissue (single cell expression profiling),the investigators will attempt to identify new genetic targets in FCD. The main outcome will be finding new causes of epilepsy with FCD and the development of new diagnostic and screening tools.


Eligibility

Inclusion Criteria5

  • Epilepsy in Focal Cortical Dysplasia Type IIA/B
  • Adult and Paediatric Patients (male and female)
  • A histologically proven diagnosis of FCDIIA/B or a suspected diagnosis of FCDIIA/B (on MRI/EEG and PET grounds) awaiting resective Epilepsy surgery.
  • Able to attend appointment/hospital and undergo sampling of serum and nasal swab
  • Informed Consent Available

Exclusion Criteria2

  • Any acute or chronic conditions that could limit the ability of the patient to participate in the study.
  • Refusal to give informed consent.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

GENETICBlood and nasal swab sampling

Genetic screening of DNA samples (blood, mucosal swab, brain tissue) from 60-100 patients with histologically confirmed diagnosis of FCDIIA/B identified from Epilepsy Surgery Databases.


Locations(1)

King's College Hospital

London, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06053671


Related Trials